Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2013-10-01 / Immunotherapy 2013 Oct;5(10):1039-42A review of dendritic cell therapy for cancer: progress and challenges
/in Dendritic Cells, International Publications /von 2013-10-01 / BioDrugs 2013 Oct;27(5):453-68Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer /von 2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2013-08-13 / Cryobiology 2013 Oct;67(2):235-40In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer
/in Cervical Cancer, Dendritic Cells, International Publications /von 2013-08-03 / Arch. Gynecol. Obstet. 2014 Jan;289(1):155-62Current status and future perspectives of dendritic cell-based cancer immunotherapy
/in Dendritic Cells, International Publications /von 2013-08-01 / Scand. J. Immunol. 2013 Aug;78(2):167-71Heat-shock proteins as dendritic cell-targeting vaccines–getting warmer
/in Dendritic Cells, Hyperthermia, International Publications /von 2013-08-01 / Immunology 2013 Aug;139(4):407-15Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium
/in Breast Cancer, Dendritic Cells, International Publications /von 2013-08-01 / Breast 2013 Aug;22 Suppl 2:S96-9Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2013-07-20 / J Gastrointest Surg 2013 Sep;17(9):1609-17IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de